Tumor cell DNA content and radiation response in head and neck squamous cell carcinoma.
Explore the source record for details and available documents.
Aneuploidy↗
Biomedical subjects
W Ichimura
Publications and source records attributed to W Ichimura.
Squamous cell carcinoma antigen in serum for monitoring of head and neck and uterine cervical squamous cell carcinomas after radiotherapy.
Squamous cell carcinoma antigen (SCC-A) in serum was serially measured during follow-up of 96 squamous cell carcinoma patients (75 head and neck cancers and 21 uterine cervical cancers), treated with radiotherapy. In 27 of the patients with head and neck cancer and in 12 of those with cervical cancer SCC-A had also been measured before radiotherapy. In this head and neck carcinoma group, the median level of SCC-A was 1.3 (95% CI: 1.2-1.9) ng/ml before radiotherapy and 1.4 (CI: 1.1-1.5) ng/ml after radiotherapy. In the cervical carcinoma group, the median SCC-A decreased significantly (p < 0.001) from a pretreatment value of 7.5 (CI: 3.8-26.3) ng/ml to a posttreatment value of 0.9 (CI: < 0.5-1.8) ng/ml. In the total group of 75 head and neck cancers 21 relapses occurred and in 4 of these the relapse was detected at a clinically silent stage by an elevation of serum SCC-A. The same was true for 4 of the 9 relapses that occurred in the total group of uterine cervical cancer. The study suggests that serum SCC-A may be useful for posttreatment monitoring of patients with uterine cervix cancer while its value in head and neck cancer probably is more marginal.
Adult↗
[Prospective dose-escalation study in stereotactic radiotherapy utilizing a linear accelerator: report from East Hokkaido Radiosurgery Study Group (EHRSSG)].
Stereotactic radiotherapy utilizing a linear accelerator has been investigated. (1) Radiosurgery, (2) fractionated stereotactic radiotherapy, and (3) fractionated radiotherapy followed by stereotactic boost have been performed according to pathology, size, and prognosis of diseases. Accuracy in localization of the treatment center was within one millimeter using a CT simulator. From July, 1990 to December 1992, 69 lesions in 63 patients have been treated using the stereotactic radiotherapy according to prospective dose-escalation design. Five patients have experienced transient worsening of nerve palsy or headache, but these complications were self-limited. No late radiation damage was observed over a mean follow-up period of 12.5 months. Encouraging improvements were obtained in patients with metastasis, AVM, and acoustic neurinoma although the follow-up period was too short to be conclusive. Stereotactic radiotherapy utilizing a linear accelerator is thus suggested as a safe and effective approach providing that dose-volume-time relationship is well controlled.
Adolescent↗